It’s only fair to share… Copper histidinate CAS 12561-67-0 AND 13870-80-9 MF C12H16CuN6O4 FDA 2026, JAN/12/26, Zycubo, To treat Menkes disease, APPROVALS 2026, 9078K3MO9U, MN 88, CUTX 101 copper bis((2S)-2-amino-3-(1H-imidazol-5-yl)propanoate) Copper histidinate, sold under the brand name Zycubo, is a medication used for the treatment of Menkes disease.[1] Copper histidinate is a copper replacement therapy given by subcutaneous injection.[1][2] …
Category «APPROVALS 2026»
Difamilast
It’s only fair to share… Difamilast FDA 2026, APPROVALS 2026, difamilast, Adquey, 2/12/2026, To treat mild to moderate atopic dermatitis PMDA Moizerto, JAPAN APPROVED 2021/9/27 ジファミラスト ディファミラスト; 地法米司特 N-({2-[4-(difluoromethoxy)-3-(propan-2-yloxy)phenyl]-1,3- oxazol-4-yl}methyl)-2-ethoxybenzamide OPA-15406 Formula C23H24F2N2O5 CAS 937782-05-3 Mol weight 446.4439 MM 36; MM-36-Medimetriks-Pharmaceuticals; Moizerto; OPA-15406 Efficacy Anti-inflammatory, Phosphodiesterase IV inhibitor Comment Treatment of atopic dermatitis OriginatorOtsuka Pharmaceutical Development …